FibroGen, Inc
FGEN Real Time Price USDRecent trades of FGEN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by FGEN's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Enhanced erythropoiesis and iron metabolism Jun. 20, 2023
-
Patent Title: Enhanced erythropoiesis and iron metabolism Jun. 20, 2023
-
Patent Title: Methods for treatment of motor neuron diseases Apr. 12, 2022
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Jan. 25, 2022
-
Patent Title: Enhanced erythropoiesis and iron metabolism Feb. 23, 2021
-
Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 19, 2021
-
Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 05, 2021
-
Patent Title: Pharmaceutical formulations of a hif hydroxylase inhibitor Sep. 08, 2020
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof May. 12, 2020
-
Patent Title: Methods for treating idiopathic pulmonary fibrosis Feb. 11, 2020
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Apr. 30, 2019
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Nov. 06, 2018
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Oct. 09, 2018
-
Patent Title: Methods for treating idiopathic pulmonary fibrosis Aug. 07, 2018
-
Patent Title: Enhanced erythropoiesis and iron metabolism Mar. 20, 2018
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Mar. 20, 2018
-
Patent Title: Compounds and methods for treatment of stroke Oct. 03, 2017
-
Patent Title: Process for making isoquinoline compounds Jul. 18, 2017
-
Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Jul. 04, 2017
-
Patent Title: Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid May. 09, 2017
-
Patent Title: Therapeutic method for pancreatic cancer Apr. 25, 2017
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Apr. 11, 2017
-
Patent Title: Treatment method for lung remodeling diseases Mar. 07, 2017
-
Patent Title: Methods for treating idiopathic pulmonary fibrosis Nov. 01, 2016
-
Patent Title: 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors Aug. 09, 2016
-
Patent Title: Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity Jul. 12, 2016
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Jun. 21, 2016
-
Patent Title: Process for making isoquinoline compounds May. 17, 2016
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof May. 17, 2016
-
Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Mar. 01, 2016
-
Patent Title: Cyanoisoquinoline compounds and methods of use thereof Nov. 03, 2015
-
Patent Title: Thiochromene derivatives as hif hydroxylase inhibitors Oct. 06, 2015
-
Patent Title: Connective tissue growth factor antisense oligonucleotides Aug. 25, 2015
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Aug. 25, 2015
-
Patent Title: Therapeutic method Aug. 11, 2015
-
Patent Title: Connective tissue growth factor antibodies May. 19, 2015
-
Patent Title: Thienopyridine compounds, and methods of use thereof Apr. 07, 2015
-
Patent Title: Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity Feb. 10, 2015
-
Patent Title: Thiochromene derivatives as hif hydroxylase inhibitors Jan. 06, 2015
-
Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Dec. 30, 2014
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Dec. 23, 2014
-
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Nov. 11, 2014
-
Patent Title: Treatments for pancreatic cancer metastases Oct. 21, 2014
-
Patent Title: Connective tissue growth factor antisense oligonucleotides Aug. 12, 2014
-
Patent Title: Methods for treatment of muscular dystrophy Jul. 08, 2014
-
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Jul. 01, 2014
-
Patent Title: Cyanoisoquinoline compounds and methods of use thereof Jun. 24, 2014
-
Patent Title: Treatments for cancer May. 20, 2014
-
Patent Title: Thienopyridine compounds, and methods of use thereof Apr. 22, 2014
-
Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 14, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of FGEN in WallStreetBets Daily Discussion
Recent insights relating to FGEN
Recent picks made for FGEN stock on CNBC
ETFs with the largest estimated holdings in FGEN
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view FGEN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.